Felicia Cosman
#165,319
Most Influential Person Now
Researcher
Felicia Cosman's AcademicInfluence.com Rankings
Felicia Cosmanlaw Degrees
Law
#2810
World Rank
#3495
Historical Rank
Common Law
#152
World Rank
#165
Historical Rank
International Law
#814
World Rank
#991
Historical Rank
Felicia Cosmanengineering Degrees
Engineering
#7290
World Rank
#8656
Historical Rank
Biomedical Engineering
#726
World Rank
#738
Historical Rank
Download Badge
Law Engineering
Why Is Felicia Cosman Influential?
(Suggest an Edit or Addition)Felicia Cosman's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. (2007) (2189)
- Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) (2083)
- Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research (2011) (1417)
- Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) (1149)
- Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research (2010) (1063)
- Romosozumab Treatment in Postmenopausal Women with Osteoporosis. (2016) (911)
- Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis (1997) (715)
- Anabolic actions of parathyroid hormone on bone. (1993) (703)
- Effects of Daily Treatment with Parathyroid Hormone on Bone Microarchitecture and Turnover in Patients with Osteoporosis: A Paired Biopsy Study * (2001) (628)
- The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT) (2011) (588)
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. (2016) (543)
- The 2017 hormone therapy position statement of The North American Menopause Society (2017) (532)
- Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. (2000) (396)
- High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis (1994) (332)
- Cytokine profile in patients with multiple sclerosis following vitamin D supplementation (2003) (318)
- Parathyroid Hormone Added to Established Hormone Therapy: Effects on Vertebral Fracture and Maintenance of Bone Mass After Parathyroid Hormone Withdrawal (2001) (307)
- Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis (2011) (289)
- Fragility fractures of the hip and femur: incidence and patient characteristics (2010) (284)
- Constant mineralization density distribution in cancellous human bone. (2003) (267)
- Males Have Larger Skeletal Size and Bone Mass Than Females, Despite Comparable Body Size (2004) (262)
- Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. (1998) (251)
- A Novel Tetracycline Labeling Schedule for Longitudinal Evaluation of the Short‐Term Effects of Anabolic Therapy With a Single Iliac Crest Bone Biopsy: Early Actions of Teriparatide (2005) (249)
- Daily and cyclic parathyroid hormone in women receiving alendronate. (2005) (243)
- Lymphocytic Hypophysitis. Report of 3 New Cases and Review of the Literature (1989) (239)
- Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. (2003) (233)
- Selective estrogen receptor modulators: clinical spectrum. (1999) (225)
- Effects Of a One‐Month Treatment With PTH(1–34) on Bone Formation on Cancellous, Endocortical, and Periosteal Surfaces of the Human Ilium (2007) (219)
- Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research (2011) (215)
- The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON‐Pivotal Fracture Trial (PFT) (2015) (213)
- Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. (1999) (198)
- Insulin-like growth factor-I in men with idiopathic osteoporosis. (1997) (198)
- Fracture history and bone loss in patients with MS (1998) (187)
- Resistance to Bone Resorbing Effects of PTH in Black Women (1997) (179)
- Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis (2017) (166)
- Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease. (1998) (163)
- Abnormal Microarchitecture and Reduced Stiffness at the Radius and Tibia in Postmenopausal Women With Fractures (2010) (159)
- High‐dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton (1994) (153)
- Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis (1993) (151)
- The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1–34)] (2004) (151)
- Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. (2010) (147)
- Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. (2009) (142)
- Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women (1995) (141)
- The Anabolic Effects of Parathyroid Hormone (2002) (137)
- Estrogen Protection against Bone Resorbing Effects of Parathyroid Hormone Infusion: Assessment by Use of Biochemical Markers (1993) (136)
- Neuropsychological features in primary hyperparathyroidism: a prospective study. (2009) (132)
- Bone mass and body composition in normal women. (1992) (125)
- Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once‐yearly zoledronic acid 5 mg: The HORIZON‐Pivotal Fracture Trial (PFT) (2012) (124)
- Determinants of stress fracture risk in United States Military Academy cadets. (2013) (117)
- Goal‐Directed Treatment for Osteoporosis: A Progress Report From the ASBMR‐NOF Working Group on Goal‐Directed Treatment for Osteoporosis (2017) (116)
- Reduced Bone Mass and Fat-Free Mass in Women with Multiple Sclerosis: Effects of Ambulatory Status and Glucocorticoid Use (1997) (114)
- Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis (2009) (113)
- Alendronate Does Not Block the Anabolic Effect of PTH in Postmenopausal Osteoporotic Women (1998) (111)
- Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial (2017) (109)
- Individual trabecula segmentation (ITS)‐based morphological analyses and microfinite element analysis of HR‐pQCT images discriminate postmenopausal fragility fractures independent of DXA measurements (2012) (109)
- Calcium Homeostasis of an Elderly Population upon Admission to a Nursing Home (1993) (108)
- ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis (2018) (107)
- Human Osteoclast Formation and Activity In Vitro: Effects of Alendronate (1998) (104)
- Bone mass and body composition in normal women (1992) (103)
- Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long‐term continuation on bone turnover and fracture risk—a perspective (2012) (101)
- Health Professional's Guide to Rehabilitation of the Patient with Osteoporosis (2003) (101)
- FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab (2018) (96)
- Is Parathyroid Hormone a Therapeutic Option for Osteoporosis? A Review of the Clinical Evidence (1998) (95)
- Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients. (1993) (90)
- Atypical Subtrochanteric and Femoral Shaft Fractures and Possible Association with Bisphosphonates (2010) (88)
- Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. (2003) (87)
- Histomorphometric Assessment of Bone Mass, Structure, and Remodeling: A Comparison Between Healthy Black and White Premenopausal Women (1997) (82)
- Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. (2005) (77)
- Anabolic and Antiresorptive Therapy for Osteoporosis: Combination and Sequential Approaches (2014) (76)
- Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene (2013) (74)
- Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblasts (2005) (73)
- Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment (2019) (73)
- Spine fracture prevalence in a nationally representative sample of US women and men aged ≥40 years: results from the National Health and Nutrition Examination Survey (NHANES) 2013-2014 (2017) (73)
- Erratum: Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research (Journal of Bone and Mineral Research (2010) 25 (2267-2294)) (2011) (72)
- Skeletal Structure in Postmenopausal Women With Osteopenia and Fractures Is Characterized by Abnormal Trabecular Plates and Cortical Thinning (2014) (70)
- Effects of Abaloparatide‐SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors (2017) (67)
- A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis (2007) (67)
- Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? (2014) (64)
- Treat-to-target for osteoporosis: is now the time? (2013) (62)
- Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome (2018) (59)
- Goal‐directed treatment of osteoporosis (2013) (59)
- Abnormal microarchitecture and stiffness in postmenopausal women with ankle fractures. (2011) (57)
- Radiographic absorptiometry: A simple method for determination of bone mass (2005) (56)
- Selective estrogen-receptor modulators. (2003) (56)
- Bone density change and biochemical indices of skeletal turnover (1996) (55)
- Comparative Assessment of Bone Mineral Measurements Using Dual X-ray Absorptiometry and Peripheral Quantitative Computed Tomography (1998) (54)
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. The Hormone Foundation, Canadian Breast Cancer Research Initiative, National Cancer Institute of Canada, Endocrine Society, and the University of Virginia Cancer Center and Woman's Place. (1999) (54)
- Vitamin D Economy in Blacks (2007) (52)
- Parathyroid Hormone-(1-34) [PTH-(l-34)]: Demonstration of Suppression of Endogenous Secretion Using Immunoradiometric Intact PTH-(l-84) Assay* (1991) (52)
- Determinants of bone mass and bone size in a large cohort of physically active young adult men (2006) (50)
- Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy (2008) (48)
- Biomechanical Computed Tomography analysis (BCT) for clinical assessment of osteoporosis (2020) (47)
- Retreatment With Teriparatide One Year After the First Teriparatide Course in Patients on Continued Long‐Term Alendronate (2009) (46)
- Microarchitectural abnormalities are more severe in postmenopausal women with vertebral compared to nonvertebral fractures. (2012) (46)
- Erratum to: Clinician’s guide to prevention and treatment of osteoporosis (2015) (44)
- Effects of estrogen on response to edetic acid infusion in postmenopausal osteoporotic women. (1994) (44)
- Stimulation of inositol phosphate formation in ros 17/2.8 cell membranes by guanine nucleotide, calcium, and parathyroid hormone (1989) (43)
- Combination therapy for osteoporosis: a reappraisal. (2014) (42)
- Relationships between quantitative histological measurements and noninvasive assessments of bone mass. (1992) (40)
- Biochemical Responses of Bone Metabolism to 1,25-Dihydroxyvitamin D Administration in Black and White Women (2000) (40)
- Effects of Cyclic Versus Daily hPTH(1‐34) Regimens on Bone Strength in Association With BMD, Biochemical Markers, and Bone Structure in Mice (2005) (39)
- A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis. (2014) (37)
- DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass (2009) (36)
- Therapeutic potential of parathyroid hormone (2004) (35)
- Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate. (2015) (35)
- Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity. (2007) (35)
- Osteoporosis : an evidence-based guide to prevention and management (2002) (34)
- The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) (2011) (33)
- The prevention and treatment of osteoporosis: a review. (2005) (33)
- Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on Alendronate (2016) (31)
- The influence of lifestyle, menstrual function and oral contraceptive use on bone mass and size in female military cadets (2007) (30)
- Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. (2009) (30)
- Treatment of osteoporosis and prevention of new fractures: role of intravenously administered bisphosphonates. (2009) (30)
- Effect of Teriparatide on Bone Formation in the Human Femoral Neck. (2016) (30)
- The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J mice. (2007) (30)
- Response of the parathyroid gland to infusion of human parathyroid hormone-(1-34) [PTH-(1-34)]: demonstration of suppression of endogenous secretion using immunoradiometric intact PTH-(1-84) assay. (1991) (28)
- The effects of hormone replacement on the biomechanical properties of the uterosacral and round ligaments in the monkey model. (2005) (28)
- Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis (2018) (28)
- Parathyroid hormone treatment improves the cortical bone microstructure by improving the distribution of type I collagen in postmenopausal women with osteoporosis (2012) (26)
- Estrogen in Prevention and Treatment of Osteoporosis a (1989) (26)
- T‐Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial (2020) (25)
- Skeletal Effects of Vitamin D Supplementation in Postmenopausal Black Women (2012) (25)
- Modeling‐Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab (2020) (24)
- Parathyroid hormone treatment for osteoporosis (2008) (23)
- Anabolic therapy for osteoporosis: Parathyroid hormone (2005) (23)
- ANABOLIC THERAPY AND OPTIMAL TREATMENT SEQUENCES FOR PATIENTS WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE. (2020) (22)
- A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates (2015) (21)
- Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis (2019) (21)
- Relationship Between Pretreatment Rate of Bone Loss and Bone Density Response to Once‐Yearly ZOL: HORIZON‐PFT Extension Study (2015) (21)
- Results of a fracture liaison service on hip fracture patients in an open healthcare system (2017) (20)
- Long-term treatment strategies for postmenopausal osteoporosis (2018) (19)
- Relationship between growth hormone in vivo bioactivity, the insulin-like growth factor-I system and bone mineral density in young, physically fit men and women. (2008) (18)
- Time to onset of antifracture efficacy and year‐by‐year persistence of effect of zoledronic acid in women with osteoporosis (2012) (18)
- Romosozumab Treatment in Postmenopausal Osteoporosis. (2017) (18)
- Parathyroid responsivity in postmenopausal women with osteoporosis during treatment with parathyroid hormone. (1998) (17)
- Changes in vitamin D metabolites during teriparatide treatment. (2012) (17)
- Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON‐PFT Extension I Trials (2019) (17)
- Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate (2008) (16)
- Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women with Osteoporosis and Varying Baseline Risk Factors (2018) (16)
- Estrogens and Osteoporosis (1983) (15)
- Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial (2020) (15)
- Eating disorders, menstrual dysfunction, weight change and DMPA use predict bone density change in college-aged women. (2016) (15)
- Responses of Urinary N-Telopeptide and Renal Calcium Handling to PTH Infusion after Treatment with Estrogen, Raloxifene, and Tamoxifen (2012) (14)
- The Pharmacology of Estrogens in Osteoporosis (2002) (14)
- Relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 8 years of denosumab treatment (2015) (14)
- Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose? (2021) (14)
- Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies. (2007) (13)
- Skeletal effects of estrogen analogs (2005) (13)
- Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review (2021) (13)
- Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial (2020) (12)
- Abaloparatide: a new anabolic therapy on the horizon. (2015) (12)
- Administration of teriparatide for four years cyclically compared to two years daily in treatment Naïve and alendronate treated women. (2019) (12)
- Romosozumab and antiresorptive treatment: the importance of treatment sequence (2022) (12)
- Double and quadruple tetracycline labeling of bone: Impact of the label itself (2013) (12)
- Parathyroid Hormone Secretory Response to EDTA-Induced Hypocalcemia in Black and White Premenopausal Women (1999) (12)
- Spine fracture prevalence in a nationally representative sample of US women and men aged ≥40 years: results from the National Health and Nutrition Examination Survey (NHANES) 2013–2014---supplementary presentation (2017) (10)
- Effect of once-yearly infusion of zoledronic acid 5 mg in postmenopausal women with osteoporosis (2007) (10)
- Postmenopausal osteoporosis: patient choices and outcomes. (1995) (10)
- Response to a letter from Anderson et al (2012) (10)
- Oral 1,25‐dihydroxyvitamin D administration in osteoporotic women: Effects of estrogen therapy (1995) (10)
- Anabolic therapy for osteoporosis: Parathyroid hormone (2006) (10)
- The evolving role of anabolic therapy in the treatment of osteoporosis. (2019) (9)
- Vitamin D receptor Fok1 polymorphism influences response to vitamin D supplementation in postmenopausal African-American women (2007) (9)
- Vertebral fracture assessment (VFA) for osteoporosis screening in US postmenopausal women: is it cost-effective? (2020) (9)
- Comparative assessment of bone mineral density of the forearm using single photon and dual X-ray absorptiometry (1992) (9)
- Influence of intermittent PTH treatment on mineral distribution in the human ilium: A paired biopsy study before and after treatment. (2001) (8)
- Effects of once-yearly zoledronic acid 5 mg in combination with teriparatide (PTH) on postmenopausal women with osteoporosis (2010) (8)
- Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis (2020) (8)
- Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial (2021) (6)
- No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients (2020) (6)
- This poster will be presented on Monday See M388 parathyroid hormone as a treatment for idiopathic osteoporosis in men Changes in bone mineral density, bone markers, and optimal duration of therapy (2000) (5)
- Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses (2022) (5)
- Chapter 51. Parathyroid Hormone Treatment for Osteoporosis (2009) (5)
- Estrogen: Effects and actions in osteoporosis (2005) (5)
- Loading modality and age influence teriparatide-induced bone formation in the human femoral neck. (2020) (4)
- Abnormal microarchitecture and stiffness in postmenopausal women with isolated osteoporosis at the 1/3 radius. (2019) (4)
- Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long‐Term Odanacatib Fracture Trial (2021) (4)
- Rationale and design of the MOTION study (monthly oral therapy with ibandronate for osteoporosis intervention). (2005) (4)
- Guest Editorial: How Long Should Patients with Osteoporosis Be Treated with Bisphosphonates? (2000) (4)
- T-score as an Indicator of Fracture Risk on Therapy: Evidence From Romosozumab vs Alendronate Treatment in the ARCH Trial (2020) (4)
- Skeletal Physiology and Osteoporosis (1994) (3)
- Estrogen, Calcium Metabolism and the Skeleton a (1991) (3)
- Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study (2022) (3)
- The treatment of osteoporosis and interaction of medications with nutrition (2003) (3)
- Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture. (2020) (3)
- Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend (2020) (3)
- Effect of once-yearly zoledronic acid 5 mg on ‘Super Six’ non-vertebral fractures (2009) (3)
- A Randomized, Double-Blind, Placebo-Controlled Study of Odanacatib (MK-822) In The Treatment of Postmenopausal Women With Low BMD: 18-Month Results (2008) (2)
- Treatment of Male Osteoporosis with Parathyroid Hormone (2010) (2)
- Effect of Once-Yearly Zoledronic Acid 5 Mg on A Sub-Set of Six Non-Vertebral Fractures (2010) (2)
- Relationship between bone mass by densitometry and by histomorphometry in primary hyperparathyroidism and in osteoporosis (1992) (2)
- Parathyroid hormone and abaloparatide treatment for osteoporosis (2018) (2)
- Exercise and milk intake are determinants of bone mass in elite military cadets. (2001) (2)
- Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis (2021) (2)
- Effects of teriparatide and loading modality on modeling-based and remodeling-based bone formation in the human femoral neck. (2022) (2)
- Percentage of women achieving non-osteoporotic BMD T-scores at the spine and hip over 8 years of denosumab treatment (2014) (2)
- Structural variables in postmenopausal women: Comparison among normal women and patients with osteoporosis or primary hyperparathyroidism (1992) (2)
- relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 10 years of Denosumab (DMAB) treatment (2016) (2)
- The Osteoporosis Primer: Selective estrogen receptor modulators (2000) (1)
- Hypercalcaemia causing declining cognitive function in a head injured patient. (1989) (1)
- Serum 25(OH)D and Calcium Intake Predict Changes in Hip BMD and Structure in Young Active Men (2013) (1)
- Body composition studies in premenopausal healthy women. (1990) (1)
- Unmasking romosozumab: response to commentsby Uzoigwe et al. (2017) (1)
- Impact of Nutrition on Medications for Osteoporosis (2015) (1)
- Erratum: Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long‐term continuation on bone turnover and fracture risk—A perspective (2012) (1)
- Short-term effects of raloxifene, tamoxifen, and estrogen on cognitive function (2002) (1)
- World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2016): Oral Communication Abstracts (2016) (1)
- Estrogen-dependent Bone Loss and Osteoporosis (2003) (1)
- OP0344 Frame study: the foundation effect of rebuilding bone with one year of romosozumab leads to continued lower fracture risk after transition to denosumab (2018) (1)
- How long should patients with osteoporosis be treated with bisphosphanates? (2000) (1)
- The Effect of Raloxifene on Bone (1998) (1)
- AFTER 3 YEARS OF ANNUAL ZOLEDRONIC ACID, WHO SHOULD REMAIN ON TREATMENT? RESULTS FROM THE HORIZON-PFT EXTENSION STUDY (2012) (1)
- EFFECT OF 6-YEAR TREATMENT OF OSTEOPOROSIS WITH ZOLEDRONIC ACID 5MG (ACLASTA) COMPARED WITH THE 3-YEAR-TREATMENT, RESULTS OF EXTENDED HORIZON PFT STUDY (2012) (1)
- Biochemical Markers in the Diagnosis and Treatment of Osteoporosis (1996) (1)
- Long-term treatment strategies and goal-directed therapy (2021) (1)
- CHAPTER 41 – Estrogen (1999) (1)
- Is there a role for combination therapy for osteoporosis? (2013) (1)
- Abaloparatide Treatment for Osteoporosis (2018) (0)
- Tension Increases Teriparatide-Induced Bone Formation More Than Compression in the Human Femoral Neck (2015) (0)
- Meeting report from the national osteoporosis foundation 5th international symposium on clinical advances in osteoporosis (2002) (0)
- Digital video photodocumentation in clinical trials to assess pelvic organ prolapse quantitation (2002) (0)
- Higher scores on the eating disorder inventory are related to bone loss in male military cadets (2007) (0)
- IOF Regional 7th Asia-Pacific Osteoporosis Conference Sydney, Australia 2018 – Oral Communications Abstracts (2018) (0)
- Relationship Between Bioassayable Growth Hormone, The Insulin‐Like Growth Factor‐I System and Bone Mineral Density in Men and Women (2007) (0)
- Motion Study of Once-Monthly Ibandronate Versus Once-Weekly Alendronate: Rationale and Design (2006) (0)
- List of contributors (2021) (0)
- CHAPTER 59 – Selective Estrogen Receptor Modulators (2007) (0)
- The effect of 6-year osteoporosis treatment withzoledronic 5 mg (aclasta) in comparison with 3-yeartreatment: results from the horizon-pft. (2011) (0)
- Skeletal Racial Differences (2011) (0)
- Determinants of Stress Fracture and Bone Mass in Elite Military Cadets (1999) (0)
- Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis (2020) (0)
- Measuring serum calcium before and after teriparatide treatment: authors’ response (2008) (0)
- 51. Parathyroid Hormone Treatment for Osteoporosis (2013) (0)
- Toward optimal health: the experts respond to osteoporosis. Interview by Jodi G. Meisler. (1998) (0)
- Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend (2023) (0)
- Fracture risk reduction with zoledronic acid by predicted fracture risk score (2011) (0)
- Teriparatide delivery by indwelling MicroChip (2012) (0)
- Persistent Fracture Reduction with Abaloparatide-SC (TYMLOS™) Followed by 24 Months of Alendronate (2018) (0)
- Books Received (2002) (0)
- Chapter 85 – Parathyroid Hormone Treatment for Osteoporosis (2013) (0)
- Relationship between change in total hip BMD in response to zoledronic acid 5 mg and pre-treatment change in total hip BMD: The HORIZON-PFT Extension study (2012) (0)
- Response to Letter to the Editor of JBMR: Treatment Sequence Matters (2017) (0)
- Percentage of women achieving non-osteoporotic BMD T-scores at the spine and hip during up to 8 years of denosumab (Dmab) treatment (2015) (0)
- Skeletal Effects of Vitamin D Supplementation in Postmenopausal Black Women (2012) (0)
- The long-term safety and efficacy of zoledronic acid in the treatment of osteoporosis: a 3-year, randomized extension to the HORIZON-pivotal fracture trial (PFT) (2011) (0)
- Chapter 82 – The Pharmacology of Estrogens in Osteoporosis (2008) (0)
- Teriparatide and abaloparatide treatment for osteoporosis (2021) (0)
- Recent insights in the use of teriparatide and antiresorptive combinations and sequences (2011) (0)
- Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals (2021) (0)
- Combination and sequential therapy for the treatment of osteoporosis (2015) (0)
- Skeletal status and effects of steroid treatment in multiple sclerosis (1992) (0)
- Paper 9: The Effect of Hormone Replacement on the Biomechanical Properties of the Uterosacral and Round Ligaments in the Macaque Monkey Model (2004) (0)
- Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis (2020) (0)
- CHAPTER 78 – Treatment with PTH Peptides (2008) (0)
- Management of Patients with Increased Fracture Risk (2018) (0)
- Are changes in bone mineralization density distribution (BMDD) related to changes in BNID and other variables of bone metabolism (2002) (0)
- Osteoporosis options. Choose medication based on age, health, and family history. (2003) (0)
- Erratum: Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long‐term continuation on bone turnover and fracture risk—A perspective (2012) (0)
- Ninth International Symposium on Osteoporosis: Translating Research into Clinical Practice (2011) (0)
- Treatment of BRONJ (2009) (0)
- Racial differences in bone mass, body composition and bone biochemistry of premenopausal women (2006) (0)
- Vitamin D Supplementation in Postmenopausal Black Women Improves Calcium Homeostasis and Bone Turnover in Three Months (2004) (0)
- Responses of Urinary N-Telopeptide and Renal Calcium Handling to PTH Infusion after Treatment with Estrogen, Raloxifene, and Tamoxifen (2012) (0)
- PTH as An Anabolic Agent (2019) (0)
- Oral ibandronate (150mg) administered monthly provides similar improvements in hip bone mineral density as oral alendronate (70mg) administered weekly in postmenopausal osteoporosis (2007) (0)
- Analysis of endometrial RNA transcripts before and after treatment with raloxifene, tamoxifen, conjugated estrogen or placebo using polymerase chain reaction (2002) (0)
- Parathyroid Hormone as Monotherapy for the Treatment of Osteoporosis (2015) (0)
- Correction: Error in Abstract (1994) (0)
- Interactions Between Calcium Intake and Antiresorptive Therapy in Osteoporosis (1998) (0)
- Percentage of women achieving non-osteoporotic BMD T-scores at the lumbar spine (LS) and total hip (TH) during up to 8 years of Denosumab (Dmab) treatment (2015) (0)
- Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis. (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Felicia Cosman?
Felicia Cosman is affiliated with the following schools:
